Low dose of emicizumab could be as effective as standard dose against Haemophilia A, according to a study led by the Indian ...

Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

A cost-effective point-of-care test kit has been developed in India for early diagnosis of haemophilia A and Von Willebrand ...

In Hooghly district, haemophilia injections have not been available at either Chinsurah Imambara Hospital or Arambagh Medical ...

The Indian Council of Medical Research's National Institute of Immunohaematology (ICMR's NIIH) has developed a cost-effective ...

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety ...

Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show ...

A patient at Guy’s and St Thomas’ recently received the first treatment in the UK of a new, potentially life-changing ...

Chugai Pharma presents positive data from NXTAGE phase I/II study of NXT007 in people with haemophilia A at ISTH 2025 Congress: Tokyo Tuesday, June 24, 2025, 13:00 Hrs [IST] Chuga ...

BJP executive member, Raman Suri has expressed concerns over the persistent non-availability of essential medicines for Haemophilia patients in Government Medical Colleges and Hospitals across J&K.

The National Institute of Immunohaematology has developed a cost-effective test kit for early diagnosis of hemophilia A and ...